

ASX RELEASE
(ASX: ISN)



Thursday 25 November 2015

**AIRSONEA RESEARCH STUDY APPROVED BY INSTITUTIONAL REVIEW BOARD
AT THE UNIVERSITY OF CHICAGO**

iSonea is pleased to advise that Institutional Review Board (IRB) approval has been received to conduct a research study of our home monitoring device, AirSonea, at the prestigious University of Chicago in the division of Medicine & Biological Sciences.

The Principal Investigator will be Professor Edward T Naureckas, MD, Professor of Medicine and Director of the Pulmonary Function Laboratory and the Adult Cystic Fibrosis Program. Dr. Naureckas is an expert in the pulmonary conditions including asthma, adult cystic fibrosis and chronic obstructive pulmonary disease (COPD). He specialises in pulmonary function testing to determine the cause and severity of complex lung disorders.

This study will collect and record breath sounds data using AirSonea platform from patients in all age groups (infants to geriatrics) under realistic ambient conditions. The study hypothesis is that the AirSonea is at least as accurate (sensitive and specific) in detection and quantifying wheeze as the consensus of: (a) physicians and (b) a panel of technical experts who evaluate these recordings.

This study will commence soon and will include 90 subjects. The duration of the study will be determined shortly.

Contact:

Mr. Peter Vaughan
Company Secretary
iSonea Limited

1800 ISONEA
1800 476 683